SR9238 | CAS#1416153-62-2 | LXR Inverse Agonist

MedKoo Cat#: 532785 | Name: SR9238

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR9238 is a potent and selective LXR inverse agonist (IC50 values are 43 and 214 nM for LXRβ and LXRα, respectively). SR9238 selectively inhibits liver LXR over peripheral LXR. Exhibits selectivity for LXR over a panel of 20 other nuclear receptors, including FXR. It reduces hepatic steatosis in obese mice.

Chemical Structure

SR9238

CAS#1416153-62-2

Theoretical Analysis

MedKoo Cat#: 532785

Name: SR9238

CAS#: 1416153-62-2

Chemical Formula: C31H33NO7S2

Exact Mass: 595.1698

Molecular Weight: 595.73

Elemental Analysis: C, 62.50; H, 5.58; N, 2.35; O, 18.80; S, 10.76

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 4,650.00	2 Weeks
2g	USD 6,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SR9238; SR 9238; SR-9238.

IUPAC/Chemical Name

ethyl 5-[[[4-(3-methylsulfonylphenyl)phenyl]methyl-(2,4,6-trimethylphenyl)sulfonylamino]methyl]furan-2-carboxylate

InChi Key

HDZWHJYZJWLTAG-UHFFFAOYSA-N

InChi Code

InChI=1S/C31H33NO7S2/c1-6-38-31(33)29-15-14-27(39-29)20-32(41(36,37)30-22(3)16-21(2)17-23(30)4)19-24-10-12-25(13-11-24)26-8-7-9-28(18-26)40(5,34)35/h7-18H,6,19-20H2,1-5H3

SMILES Code

O=C(C1=CC=C(CN(CC2=CC=C(C3=CC=CC(S(=O)(C)=O)=C3)C=C2)S(=O)(C4=C(C)C=C(C)C=C4C)=O)O1)OCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SR9238 is an LXR inverse agonist (IC50 values are 43 and 214 nM for LXRβ and LXRα, respectively). SR9238 selectively inhibits liver LXR over peripheral LXR. SR9238 exhibits selectivity for LXR over a panel of 20 other nuclear receptors, including FXR.

In vitro activity:

To be determined

In vivo activity:

Liver-selective LXR inverse agonists may hold utility in the treatment of liver disease. Treatment of diet-induced obese mice with SR9238 suppressed plasma cholesterol levels. SR9238 effectively suppressed hepatic lipogenesis, inflammation, and hepatic lipid accumulation in a mouse model of non-alcoholic hepatosteatosis. SR9238 displays high potency for both LXRα and LXRβ (40-200 nM IC50). Reference: ACS Chem Biol. 2013 Mar 15;8(3):559-67. https://pubmed.ncbi.nlm.nih.gov/23237488/

	Solvent	mg/mL	mM	comments
Solubility
	DMSO	59.6	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 595.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Sengupta M, Griffett K, Flaveny CA, Burris TP. Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. ACS Pharmacol Transl Sci. 2018 Sep 14;1(1):50-60. doi: 10.1021/acsptsci.8b00003. Epub 2018 Jul 25. PMID: 31696159; PMCID: PMC6834356. 2. Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67. doi: 10.1021/cb300541g. Epub 2012 Dec 27. PMID: 23237488.

In vitro protocol:

To be determined

In vivo protocol:

1: Elgendy B, Griffett K, Hegazy L, Di Fruscia P, Sample K, Schoepke E, Kamenecka TM, Burris TP. Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorg Chem. 2022 Feb;119:105540. doi: 10.1016/j.bioorg.2021.105540. Epub 2021 Dec 7. PMID: 34902646. 2: Sengupta M, Abuirqeba S, Kameric A, Cecile-Valfort A, Chatterjee A, Griffett K, Burris TP, Flaveny CA. A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis. PLoS One. 2021 Mar 26;16(3):e0249316. doi: 10.1371/journal.pone.0249316. PMID: 33770118; PMCID: PMC7996992. 3: Toporova L, Grimaldi M, Boulahtouf A, Balaguer P. Assessing the Selectivity of FXR, LXRs, CAR, and RORγ Pharmaceutical Ligands With Reporter Cell Lines. Front Pharmacol. 2020 Jul 24;11:1122. doi: 10.3389/fphar.2020.01122. PMID: 32792956; PMCID: PMC7394005. 4: Zeng J, Wu D, Hu H, Young JAT, Yan Z, Gao L. Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes. Hepatology. 2020 Dec;72(6):1935-1948. doi: 10.1002/hep.31217. PMID: 32145089. 5: Hu W, Jia Y, Kang Q, Peng H, Ma H, Zhang S, Hiromori Y, Kimura T, Nakanishi T, Zheng L, Qiu Y, Zhang Z, Wan Y, Hu J. Screening of House Dust from Chinese Homes for Chemicals with Liver X Receptors Binding Activities and Characterization of Atherosclerotic Activity Using an in Vitro Macrophage Cell Line and ApoE-/- Mice. Environ Health Perspect. 2019 Nov;127(11):117003. doi: 10.1289/EHP5039. Epub 2019 Nov 14. PMID: 31724879; PMCID: PMC6927504. 6: Sengupta M, Griffett K, Flaveny CA, Burris TP. Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. ACS Pharmacol Transl Sci. 2018 Sep 14;1(1):50-60. doi: 10.1021/acsptsci.8b00003. Epub 2018 Jul 25. PMID: 31696159; PMCID: PMC6834356. 7: Griffett K, Burris TP. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochem Biophys Res Commun. 2016 Oct 21;479(3):424-428. doi: 10.1016/j.bbrc.2016.09.036. Epub 2016 Sep 25. PMID: 27680310; PMCID: PMC5087326. 8: Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol Metab. 2015 Feb 9;4(4):353-7. doi: 10.1016/j.molmet.2015.01.009. PMID: 25830098; PMCID: PMC4354919. 9: Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP. A liver- selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67. doi: 10.1021/cb300541g. Epub 2012 Dec 27. PMID: 23237488.